These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35500559)

  • 1. The Correlation of Fibroblast Growth Factor 23 with Cardiac Remodeling in Essential Hypertension with Normal Renal Function.
    Han J; Yuan X; Song W; Cheng Y; Lu Y; Zhang Y; Liu Y; Jiang Y
    Cardiology; 2022; 147(3):271-280. PubMed ID: 35500559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).
    Dörr K; Kammer M; Reindl-Schwaighofer R; Lorenz M; Loewe C; Marculescu R; Erben R; Oberbauer R
    Trials; 2019 Oct; 20(1):601. PubMed ID: 31651370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in serum and intracardiac fibroblast growth factor 23 during the progression of left ventricular hypertrophy in hypertensive model rats.
    Fujii H; Watanabe K; Kono K; Goto S; Watanabe S; Nishi S
    Clin Exp Nephrol; 2019 May; 23(5):589-596. PubMed ID: 30539338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the implications of blocking renin-angiotensin-aldosterone system and fibroblast growth factor 23 in early left ventricular hypertrophy without chronic kidney disease.
    Watanabe K; Fujii H; Okamoto K; Kono K; Goto S; Nishi S
    Front Endocrinol (Lausanne); 2023; 14():1276664. PubMed ID: 38174329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.
    Jovanovich A; Ix JH; Gottdiener J; McFann K; Katz R; Kestenbaum B; de Boer IH; Sarnak M; Shlipak MG; Mukamal KJ; Siscovick D; Chonchol M
    Atherosclerosis; 2013 Nov; 231(1):114-9. PubMed ID: 24125420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypericin Alleviates Chronic Kidney Disease-induced Left Ventricular Hypertrophy by Regulation of FGF23-FGFR4 Signaling Pathway.
    Liu M; Cheng L; Ye Q; Liu H; Shu C; Gao H; Liu X; Zhang X; Chen G
    J Cardiovasc Pharmacol; 2024 Jun; 83(6):588-601. PubMed ID: 38547517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
    Leifheit-Nestler M; Grabner A; Hermann L; Richter B; Schmitz K; Fischer DC; Yanucil C; Faul C; Haffner D
    Nephrol Dial Transplant; 2017 Sep; 32(9):1493-1503. PubMed ID: 28339837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.
    Cataliotti A; Malatino LS; Jougasaki M; Zoccali C; Castellino P; Giacone G; Bellanuova I; Tripepi R; Seminara G; Parlongo S; Stancanelli B; Bonanno G; Fatuzzo P; Rapisarda F; Belluardo P; Signorelli SS; Heublein DM; Lainchbury JG; Leskinen HK; Bailey KR; Redfield MM; Burnett JC
    Mayo Clin Proc; 2001 Nov; 76(11):1111-9. PubMed ID: 11702899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between plasma fibroblast growth factor-23 and subclinical cardiovascular damages in children with primary hypertension].
    Lin Y; Shi L; Liu YY; Zhang HW; Liu Y; Zhang MM; Huang XL; Hou DQ; Cui XD
    Zhonghua Er Ke Za Zhi; 2019 Jun; 57(6):471-476. PubMed ID: 31216806
    [No Abstract]   [Full Text] [Related]  

  • 10. NLR-A Simple Indicator of Inflammation for the Diagnosis of Left Ventricular Hypertrophy in Patients with Hypertension.
    Yu X; Xue Y; Bian B; Wu X; Wang Z; Huang J; Huang L; Sun Y
    Int Heart J; 2020 Mar; 61(2):373-379. PubMed ID: 32173694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.
    Magnusson M; Jovinge S; Rydberg E; Dahlöf B; Hall C; Nielsen OW; Grubb A; Willenheimer R
    Blood Press; 2009; 18(4):196-203. PubMed ID: 19562575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients.
    Khan IA; Fink J; Nass C; Chen H; Christenson R; deFilippi CR
    Am J Cardiol; 2006 May; 97(10):1530-4. PubMed ID: 16679099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-type natriuretic peptide and left ventricular hypertrophy in hypertensive patients.
    Almeida P; Azevedo A; Rodrigues R; Dias P; Friões F; Vazquez B; Abreu-Lima C; Bettencourt P; Barros H
    Rev Port Cardiol; 2003 Mar; 22(3):327-36. PubMed ID: 12847875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
    Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.
    Grabner A; Schramm K; Silswal N; Hendrix M; Yanucil C; Czaya B; Singh S; Wolf M; Hermann S; Stypmann J; Di Marco GS; Brand M; Wacker MJ; Faul C
    Sci Rep; 2017 May; 7(1):1993. PubMed ID: 28512310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct and indirect effects of fibroblast growth factor 23 on the heart.
    Nakano T; Kishimoto H; Tokumoto M
    Front Endocrinol (Lausanne); 2023; 14():1059179. PubMed ID: 36909314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.
    Hsu HJ; Wu MS
    Am J Med Sci; 2009 Feb; 337(2):116-22. PubMed ID: 19214027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 23 in children with or without heart failure: a prospective study.
    Elzayat RS; Bahbah WA; Elzaiat RS; Elgazzar BA
    BMJ Paediatr Open; 2023 Feb; 7(1):. PubMed ID: 36828640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Fibroblast Growth Factor 23 as a Biomarker for Severe Cardiac Impairment in Children with Chronic Kidney Disease: A Single Tertiary Center Study.
    Palupi-Baroto R; Hermawan K; Murni IK; Nurlitasari T; Prihastuti Y; Sekali DRK; Ambarsari CG
    Int J Nephrol Renovasc Dis; 2021; 14():165-171. PubMed ID: 34135617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of soluble ST2 in patients with essential hypertension and its relationship with left ventricular hypertrophy.
    Wei P; Liu L; Wang X; Zong B; Liu X; Zhang M; Fu Q; Wang L; Cao B
    ESC Heart Fail; 2023 Feb; 10(1):303-310. PubMed ID: 36210061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.